Presymptomatic autoantibodies in Sjögren's syndrome: what significance do they hold for the clinic?

Research output: Contribution to journalDebate/Note/Editorialpeer-review

Abstract

In a number of autoimmune diseases, for example, rheumatoid arthritis and systemic lupus erythematosus, it is known that autoantibodies are present before the clinical onset. Recently we have shown that autoantibodies can be found many years before symptom onset in primary Sjögren's syndrome. This implies that screening for autoantibodies may be used to identify individuals at risk of developing systemic autoimmune disease. Possibly, autoantibody screening may also contribute to detection of incipient malignancy. This concept stems from a novel finding, on scleroderma patients, suggesting that an anti-tumor immune response elicited by a mutated self-antigen will cross-react with the unmodified version of the self-antigen, and thus come to trigger the formation of autoantibodies.
Original languageEnglish
Pages (from-to)815-817
JournalExpert Review of Clinical Immunology
Volume10
Issue number7
DOIs
Publication statusPublished - 2014

Subject classification (UKÄ)

  • Immunology in the medical area

Fingerprint

Dive into the research topics of 'Presymptomatic autoantibodies in Sjögren's syndrome: what significance do they hold for the clinic?'. Together they form a unique fingerprint.

Cite this